3-Mar-2022 11:05 AM EST Add to Favorites
Positive trends in global education access are expected to decrease dementia prevalence worldwide by 6.2 million cases by the year 2050.
28-Jul-2021 8:05 AM EDT Add to Favorites
Alzheimer's Association Welcomes CMS Announcement of National Coverage Determination Analysis on Treatment for Alzheimer's Disease
On behalf of all those living with Alzheimer's disease, their caregivers, and their families, we appreciate the Centers for Medicare & Medicaid Services (CMS) thoughtful consideration on coverage considerations for monoclonal antibodies targeting...
13-Jul-2021 8:45 AM EDT Add to Favorites
Aduhelm has been approved for use for those with Mild Cognitive Impairment or early stage Alzheimer's dementia. This treatment offers a marginal but potentially meaningful slowing of decline for this subpopulation of individuals with Alzheimer's...
12-Jul-2021 8:45 AM EDT Add to Favorites
The Alzheimer's Association is pleased with the announcement today that the Food and Drug Administration (FDA) has revised the prescribing label for Aduhelm™ (aducanumab).
8-Jul-2021 6:00 PM EDT Add to Favorites
As the global nonprofit leader in Alzheimer's research and science we have extensively reviewed the clinical trial data for Aduhelm™ (aducanumab).
14-Jun-2021 8:05 AM EDT Add to Favorites
A simple blood test for Alzheimer’s would be a great advance for individuals with — and at risk for — the disease, families, doctors and researchers.
27-Jul-2020 9:05 AM EDT Add to Favorites
Primary Care Physicians on the Front Lines of Diagnosing and Providing Alzheimer’s and Dementia Care: Half Say Medical Profession Not Prepared to Meet Expected Increase in Demands
- Report provides latest Alzheimer’s prevalence, incidence, mortality and costs of care data -
- Barring medical breakthroughs, the number of people age 65+ with Alzheimer’s dementia may nearly triple by 2050 -
11-Mar-2020 8:00 AM EDT Add to Favorites
See All News
7-Jun-2021 12:20 PM EDT
2-Jun-2021 3:45 PM EDT
26-Mar-2020 4:45 PM EDT